AbbVie Inc. $ABBV Shares Purchased by 111 Capital

111 Capital lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 68.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 7,442 shares of the company’s stock after acquiring an additional 3,031 shares during the quarter. 111 Capital’s holdings in AbbVie were worth $1,700,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Chelsea Counsel Co. acquired a new stake in AbbVie during the 3rd quarter valued at $26,000. Westend Capital Management LLC acquired a new position in AbbVie during the fourth quarter valued at $29,000. Texas Capital Bancshares Inc TX purchased a new stake in AbbVie in the 3rd quarter worth about $31,000. Legacy Wealth Managment LLC ID boosted its position in AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the period. Finally, WestEnd Advisors LLC boosted its position in AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ABBV shares. Evercore set a $235.00 target price on AbbVie in a report on Friday, May 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $240.00 price objective on shares of AbbVie in a research report on Thursday, April 30th. Canaccord Genuity Group lifted their target price on shares of AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Guggenheim restated a “buy” rating and set a $249.00 price target on shares of AbbVie in a report on Friday, May 1st. Finally, DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $253.43.

AbbVie Stock Up 1.2%

ABBV stock opened at $227.68 on Friday. AbbVie Inc. has a twelve month low of $181.73 and a twelve month high of $244.81. The company has a market cap of $402.27 billion, a PE ratio of 112.16, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. The business’s 50-day simple moving average is $209.85 and its 200 day simple moving average is $219.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter last year, the company earned $2.46 earnings per share. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, equities research analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s ovarian cancer drug Elahere received a green light from the UK’s NHS / drug-cost watchdog, improving access and potential sales in a major international market. British drug-cost watchdog recommends use of AbbVie’s ovarian cancer therapy
• Positive Sentiment: AbbVie also won European Commission approval for Aquipta to treat migraine, which could expand the drug’s commercial opportunity in Europe. AbbVie receives EC approval for Aquipta to treat migraine
• Positive Sentiment: AbbVie’s FDA approval of Decnupaz for BPDCN was highlighted as validation of its ADC oncology strategy, reinforcing confidence in the company’s long-term cancer pipeline. Does Decnupaz Approval Validate ABBV’s ADC Strategy in Oncology?
• Positive Sentiment: AbbVie completed a real-world study of upadacitinib in China and finished a bioavailability study for ABBV-932, both of which support ongoing pipeline development. AbbVie Completes Real World Upadacitinib Study in China AbbVie Advances ABBV-932 With Completed Bioavailability Study
• Neutral Sentiment: AbbVie was also featured in value-stock and “cheap stocks” roundups, which may reflect its appeal to investors but are not direct company-specific catalysts. 5 Best Cheap Stocks to Buy for Beginners June 2026’s Top Stocks Estimated Below Intrinsic Value
• Negative Sentiment: AbbVie ended an early lung cancer trial for ABBV-647, which removes one potential upside driver from the oncology pipeline, though the broader impact appears limited. AbbVie Ends Early Lung Cancer Trial for ABBV-647

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.